Toxicity in patients treated with permanent prostate brachytherapy using intraoperatively built custom-linked seeds versus loose seeds

Luc Ollivier, MD1,2, Francois Lucia, MD1,2,3, Tuongan Nguyen, MD4, Caroline Lucas, MD4, Vincent Bourbonne, MD1,2,3, Nicolas Boussion, MSc, PhD1,2, Gaëlle Goasduff, MSc1, Georges Fournier, MD, PhD2,3,4, Olivier Pradier, MD, PhD1,2,3, Gurvan Dissaux, MD1,2,3, Antoine Valeri, MD, PhD2,3,4, Ulrike Schick, MD, PhD1,2,3

1Service de Radiothérapie, CHU Brest, Brest, France, 2Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France, 3LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France, 4Service d’Urologie, CHU Brest, Brest, France

Abstract

Purpose: Low-dose-rate brachytherapy (BT) with permanent iodine-125 radioactive seeds is a highly effective treatment option for low- and favorable intermediate-risk prostate cancer. However, optimal implantation is not always achieved due to edema or seeds loss. One way to improve seed placement is the use of stranded seeds called “intraoperatively built custom-linked seeds (IBCLS)” in opposition to loose seeds (LS). To date, there are few data comparing toxicity rates between these two techniques. The aim of this study was to compare dosimetric parameters and toxicity rates at 2 years between both procedures in a matched-paired population.

Material and methods: Patients were considered for BT according to European guidelines. Among 548 patients treated at our institution, 105 patients in the loose seeds cohort were individually matched to 105 patients in the IBCLS group according to age, prostate volume, pre-operative international prostate symptom score (IPSS), clinical stage, and Gleason score. Erectile function was scored using the five-item international index of erectile function (IIEF-5) score. A multivariable linear mixed-effects model was applied to examine the association between total and individual scores (repeated measures) and covariates.

Results: Overall, 61 (29%) patients presented with a favorable intermediate-risk prostate cancer. There were no significant changes in IPSS over time ($p = 0.57$). During follow-up, the IIEF-5 was similar in the two groups, except at one month, where it was lower in the IBCLS group (10.9 vs. 6.9, $p = 0.029$). Also, there was no difference in grade ≥ 2 rectal toxicity. At 1 month, $D_{90\text{Gy}}$, $V_{150\%}$, and $V_{100\%}$ were higher in the LS group compared to the IBCLS group.

Conclusions: Low-dose-rate prostate brachytherapy using IBCLS is a safe technique, with comparable toxicity profiles at 2 years compared to LS brachytherapy.

J Contemp Brachytherapy 2020; 12, 6: 547–553
DOI: https://doi.org/10.5114/jcb.2020.101687

Key words: prostate cancer, brachytherapy, loose seed, linked seed, LDR.
The aim of this study was to compare the acute and one-year toxicities of both procedures in a matched-paired population.

Material and methods

Patients

This work is a mono-centric retrospective study with prospective assessment. Between 2003 and 2018, 548 patients were treated with permanent prostate low-dose BT with $^{125}$I seeds for a low-risk or a favorable intermediate-risk adenocarcinoma prostate cancer, according to D’Amico classification at our institution. Patients were considered for BT with the following criteria: 1. Gleason score $< 7$ with prostate-specific antigen (PSA) $< 10$ ng/ml and $< T2b$, or PSA 10-15 ng/ml or T2b, or Gleason score 7 (3 + 4); 2. $\leq 50\%$ of positive biopsies; 3. Initial prostate volume $\leq 60$ cc as measured by transrectal ultrasound [6]. Patients with previous external radiotherapy to the pelvis or those who received androgen deprivation to decrease prostate volume before the procedure were not considered. Patients were included in the analysis if they have completed at least 24 months of follow-up.

A matching process using the Excel® match function was undertaken from the entire patient cohort to produce two similar groups of patients, depending on the brachytherapy seeds technique. Patients in the LS cohort were individually matched to patients in the IBCLS cohort. We did not consider the first 40 patients in the loose seeds group in order to exceed the learning curve [7]. On the opposite, the IBCLS procedure does not require a learning curve after an LS experience [8]. Matching was performed according to the following factors: age, prostate volume, pre-operative international prostate symptom score (IPSS), clinical stage, and Gleason score. Weights were assigned in order of importance on the IPSS, TNM stage, prostate volume, Gleason score, and age. Because the number of patients treated with IBCLS ($n = 123$; 13 patients without at least 24 months of follow-up regarding the date of implantation seeds) was smaller than that of patients treated with LS ($n = 425$), 110 patients were randomly selected from the LS group to match the distribution. When a matched-pair could not be obtained, patients were excluded from the analysis. After several repeats of matching and exclusion, 105 patients with brachytherapy procedure using LS and 105 matched patients with IBCLS were selected for the study population.

Treatment

The choice of treatment was made by the patient after clear and fair information of the benefits and side effects of each available curative option. All patients underwent an ultrasonography volume study at 2-6 weeks before the implantation to determine the number of seeds.

Iodine-125 BT procedures were performed by the same experienced team, including an urologist, a radiation oncologist, and a physicist, using real-time dynamic dosimetric planning, as described by Stone and Stock [9], with patients in an extended lithotomy position and under general anesthesia. Using a transrectal ultrasound probe attached to the stepper, transverse images from the base to the apex of the prostate were captured at 5-mm intervals and were loaded into the treatment planning software (Variseed, Varian Medical Systems, Palo Alto, CA, USA). The prostate (excluding seminal vesicles), urethra (with a balloon catheter), and rectal wall were outlined. Interstitial needles were inserted into the prostate through a perineal template under sagittal and axial transrectal ultrasound image guidance. Each needle location was registered in real-time on the treatment planning computer. A secondary image capture was performed after needle insertion, and the contours of all of the structures were revised. Next, a dosimetric plan, which accounted for prostate movement and swelling after needle insertion, was generated.

Once the plan was approved, $^{125}$I loose seeds or intraoperatively custom-linked seed trains were manually placed into the prostate. In our institution, loose seed were used up to 2016, and were then replaced by IBCL, which combines seeds and connectors into seed trains of variable length, with variables seed-to-seed spacing as predetermined by planning.

Endorectal ultrasound imaging allowed a real-time visualization of the implantation to assure appropriate placement of the seed/train. The computer provided a real-time dynamic dosimetric evaluation of the implant, allowing the plan to be corrected during the procedure if needed.

The technique of $^{125}$I BT was carried out, with a prescribed dose of 160 Gy. The dose constraints used for organs at risk were as follows: for the urethra: $D_{90} < 218$ Gy, $D_{100} < 188$ Gy; for the rectum: $D_{2cc} < 145$ Gy, $D_{0.1cc} < 200$ Gy. To assess the reproducibility of dosimetric plan, the $\Delta D_{90}$, which is the absolute change in the minimum dose received by 90% of the prostate volume between the intraoperative and post-operative planning, was calculated ($\Delta D_{90} = post-operative D_{90} - intraoperative D_{90}$). If the absolute change in prostate $D_{90}$ ($\Delta D_{90} = post-operative D_{90} - intraoperative D_{90}$) is low, the plan reproducibility is considered to be high [10].

Post-implantation dosimetry

On the operative day, patients underwent a cystogram as well as a chest X-ray to exclude bladder and lung seed migration. Patients were requested to strain their urines during the first 15 days after the procedure.

One month after the implantation, patients underwent a pelvic computer tomography with 2-mm slice images (Philips Aura CT Scanner, Philips Medical Systems, Best, The Netherlands) [11]. The images were uploaded into the Variseed v.9.0 treatment planning system (Varian Medical Systems, Inc., Palo Alto, CA, USA), and the prostate and rectum were then outlined. During the implantation, the urethra was defined based on the urethral catheter, and was contoured from the bladder neck to the prostatic apex under sagittal and axial transrectal ultrasound image guidance. The patients were not catheterized for the post-operative CT scan, therefore, only the peri-operative dose to the urethra was reported in this study. The location of the BT seeds was defined by a com-
bination of manual and automated redundancy checks available on the Variseed software system.

**Toxicity assessment and follow-up**

Toxicities were assessed using the international prostate symptom score (IPSS) [12] and the five-item international index of erectile function (IIEF-5) [13]. IPSS class were considered as follows: mild (0-7), moderate (8-19), or severe (20-35). The IIEF-5, also known as SHIM (sexual health inventory for men), is a validated self-administered questionnaire, which allows to classify erectile dysfunction in different classes according to the score obtained, including no erectile dysfunction (ED): > 21, weak ED: 21-17, weak to moderate ED: 16-12, moderate ED: 11-8, severe ED: < 8. The clinical impact of erectile toxicity was reported by the change in IIEF-5 class between the pre-operative IIEF-5 (if superior to 16) and IIEF-5 at first and second year. Rectal symptoms were scored using the common terminology criteria for adverse events (CTCAE) v.4 [14]. All patients started α-1 adrenergic antagonist therapy immediately after BT, for a 6 months duration. As patients after LDR brachytherapy fail to improve quality of life within 12 months after seed implantation [15], we do not routinely prescribe cyclooxygenase-2 (COX-2) inhibitors.

**Statistical method**

Descriptive statistics were used for patients’ demographics, procedures characteristics, dosimetric variables, CTCAE toxicities, and IPSS and IIEF-5 scores as well as clinical outcomes. The normality of the IPSS distribution was tested using Shapiro-Wilk test. The mean and standard deviations of questionnaire scores at baseline and follow-up were calculated. A multivariable linear mixed-effects model was used to describe the change of IPSS, including prostate volume, age, brachytherapy technique, and time to visit, as covariates. Statistical significance was defined as a two-tailed \( p \)-value < 0.05. All analyses were conducted using a R stat software version 3.6.0.

**Results**

The median follow-up of the entire cohort was 83.3 months (range, 29.5-207.4 months). Patients characteristics of the entire group are displayed in Table 1.

**Matched-paired patients and tumor characteristics**

There were no differences in patients’ characteristics between the two groups after the matched-paired procedure (Table 2). For the entire cohort, the mean age was 64.87 years, and 61 (29%) patients presented with a favorable intermediate-risk prostate cancer. Seven patients were lost to follow-up and were censored at date of last available PSA.

**Dosimetric considerations**

The IBCLS technique required fewer needles (21.4 vs. 18.4, \( p < 0.001 \)), but a similar number of seeds (64.5 vs. 62.3, \( p = 0.068 \)) than the LS procedure. Seeds migration

| Table 1. Patients characteristics of the whole cohort |
|-------------|------------------|----------------|
|             | Loose seeds \( n = 427 \) | Intraoperatively built custom-linked seeds \( n = 121 \) | \( \text{P-value} \) |
| Age (years) mean (SD) | 65.43 (6.1) | 64.6 (5.5) | 0.21 |
| Prostate volume (cc) mean (SD) | 42.9 (11.9) | 40.8 (11.2) | 0.10 |
| Gleason score (%) | 2 | 1 (0.2) | 0 (0.0) | < 0.01 |
| 4 | 5 (1.2) | 0 (0.0) |
| 5 | 19 (4.4) | 0 (0.0) |
| 6 | 378 (88.5) | 90 (74.4) |
| 7 | 24 (5.6) | 31 (25.6) |

| | Intermediate-risk prostate cancer |
|-------------|---------------------|
| Androgen deprivation | 63 | 6 | 0.01 |

| SD – standard deviation |

| Table 2. Patients’ characteristics |
|-------------|------------------|-------------|----------------|
|             | Loose seeds \( n = 105 \) | Intraoperatively built custom-linked seeds \( n = 105 \) | \( \text{P-value} \) |
| Age (years) mean (SD) | 64.8 (5.9) | 64.9 (5.4) | 0.96 |
| Prostate volume (cc) mean (SD) | 41 (10.4) | 41.2 (11.2) | 0.86 |
| Gleason score mean (SD) | 6.2 (0.4) | 6.2 (0.4) | 0.87 |
| T stage % mean (SD) | 62 | 51 | 0.57 |

| | Intermediate-risk prostate cancer |
|-------------|---------------------|
| T1c | 99 (94.3) | 99 (94.3) | 1.00 |
| T2a | 6 (5.7) | 6 (5.7) |
| Intermediate-risk prostate cancer | 28 | 33 | 0.57 |
to the lungs occurred in one patient in the LS group and one patient in the IBCLS group. No patients reported seeds loss after the procedure. There was no difference in peri-operative parameters $D_{90\text{Gy}}$ (180.0 Gy vs. 179.8 Gy, $p = 0.65$) and $V_{100\%}$ (96.7% vs. 96.7%, $p = 0.93$), in the LS and IBCLS groups, respectively, but a lower $V_{150\%}$ in the IBCLS group (51.9% vs. 48.8%, $p < 0.001$). At 1 month, $D_{90\text{Gy}}$, $V_{150\%}$, and $V_{100\%}$ were higher in the LS group compared to the IBCLS group (166.2 Gy vs. 150.4 Gy, $p < 0.001$; 60.5% vs. 52.1%, $p < 0.001$; 92.2% vs. 90.7%, $p = 0.003$, respectively) (Table 3).

The reproducibility of the dosimetric plan was better in patients treated with loose seeds, with a mean $\Delta D_{90\text{Gy}}$ of $-13.6 \pm 16.43\%$ in the LS group compared to $-29.3 \pm 8.02\%$ in the IBCLS group ($p < 0.001$).

Regarding organs at risk, the peri-operative doses to the rectum and urethra were higher in the LS group compared to the IBCLS group. The maximum dose to the rectum and urethral $D_{10\%}$ were 113.5 Gy vs. 107.8 Gy, $p = 0.002$, and 190.5 Gy vs. 185.8 Gy, $p < 0.001$ in the LS and IBCLS groups, respectively (Table 3). At one month, there was no difference in $D_{2\text{cc}}$ to the rectum (108.4 Gy vs. 109.2 Gy, $p = 0.539$) or in $D_{0.1\text{cc}}$ (179.6 Gy vs. 185.5 Gy, $p = 0.384$).

**Toxicity outcomes**

Questionnaires of IPSS and IIEF-5 were completed by all patients before BT, at one, and 3 months after the procedure, and every 6 months thereafter for 5 years.

Patients in the IBCLS group had a lower IPSS than those in the LS group at three month (13.1 vs. 15.6, $p = 0.020$) and at one year (8 vs. 10, $p = 0.022$) (Figure 1, Table 4). Change for a superior IPSS class at one year occurred more often in patients treated with LS (43% vs. 27%, $p = 0.027$), but at 1, 6, 18, and 24 months post-procedure, IPSS scores were similar in the two groups, with no difference in the consumption of alpha blocker at 1 year (32% vs. 25%, $p = 0.43$ in the LS and IBCLS groups, respectively). According to the linear mixed-effects model, there was no significant IPSS changes over time ($p = 0.57$).

Two patients in the LS group and one in the IBCLS group experienced acute urinary retention.

Erectile dysfunction was similar in the two groups, except at one month, where the IIEF-5 was lower in the IBCLS group (10.9 vs. 6.9, $p = 0.029$).

Digestive toxicity was also assessed at each follow-up visit. Grade $\geq 2$ rectal toxicity was observed at 1 month (1%) in 2 patients in the LS group (Table 4) vs. none in the other group. A transitional difference was observed at 6 months in favor of the LS group; indeed, the rate of grade 1 toxicity was 16.1% in patients treated with IBCLS vs. 4.7% with LC ($p = 0.008$). However, from one year on, no difference was noted between the 2 groups.

**Outcomes**

One patient in the LS group and two in the IBCLS group had a biochemical recurrence 2 years after the implantation (2 pelvic lymph nodes relapses, and one metastatic recurrence).

**Discussion**

To our knowledge, this is the first study comparing toxicity outcome between stranded seeds and LS for low-dose-rate prostate BT at 24 months after the BT procedure.
Toxicity outcome after BT are highly correlated with the existence of pre-operative urinary symptoms. Here, the mean pre-implantation IPSSs observed in each group are consistent with the literature in both the LS (5.3) and the IBCLS (5.2) cohorts, and were comparable between the 2 groups as IPSS was a criteria for matching. Zuber et al. reported a mean IPSS of 6.3 ±4.0 in a population of 169 patients before treatment, but 25% of them received neoadjuvant androgen deprivation, which is known to improve urinary symptoms [16]. In another study on 195 patients, who did not receive hormonal treatment, the mean IPSS before treatment and at one year post-therapy was 4.5 ±3.8 and 7.9 ±5.6, respectively [17]. In our study, patients in the IBCLS group had a significantly lower IPSS at 12 months compared to patients in the LS group (8.03 vs. 10.00), with no difference in the consumption of alpha blockers at 1 year (32% vs. 25%, \( p = 0.43 \)). This may be explained by the lower urethra dosimetric parameters, especially the \( D_{10\%} \) and \( D_{30\%} \) obtained with IBCLS compared to LS. However, an opposite results were reported by Major et al., who observed less intraoperative dose to rectum and urethra with LS compared to stranded seeds, but a slightly worse target coverage [18]. Recently, anatomic subregions have been identified as involved in ureterovesical symptoms, namely the posterior part of the bladder, which dose was shown to be predictive of late retention and dysuria in external radiotherapy [19]. As less local seeds migrations are observed with the IBCLS technique [8,11], it can be hypothesized that lower dosimetric parameters to the urethra and less irradiation of the bladder mucosa result from the use of IBCLS [3].

Table 4. Toxicity occurrence in each group

|                     | Loose seeds \( n = 105 \) | Intraoperatively built custom-linked seeds \( n = 105 \) | \( P \)-value |
|---------------------|--------------------------|------------------------------------------|--------------|
| **IPSS before implantation** | 5.3 (3.8) | 5.2 (3.7) | 0.89 |
| at 1 month | 15.08 (8.5) | 13.41 (7.6) | 0.19 |
| at 3 months | 15.63 (8.3) | 13.13 (6.9) | 0.02 |
| at 6 months | 11.30 (7.0) | 10.40 (7.2) | 0.38 |
| at 12 months | 10.00 (6.6) | 8.03 (5.6) | 0.02 |
| at 18 months | 8.24 (5.6) | 8.28 (5.8) | 0.96 |
| at 24 months | 7.62 (5.5) | 7.18 (5.3) | 0.58 |
| **α-blockers intake** | | | |
| at 12 months | 32% | 25% | 0.43 |
| at 18 months | 23% | 18% | 0.49 |
| at 24 months | 20% | 9% | 0.06 |
| **IEEF-5 at baseline** | 16.01 (8.5) | 17.18 (7.2) | 0.30 |
| at 1 month | 10.94 (8.2) | 6.97 (8.3) | 0.03 |
| at 3 months | 12.05 (8.8) | 11.82 (8.3) | 0.86 |
| at 6 months | 13.05 (8.7) | 15.23 (8.1) | 0.13 |
| at 12 months | 12.86 (8.4) | 14.68 (7.7) | 0.06 |
| at 18 months | 14.70 (7.9) | 14.98 (6.5) | 0.84 |
| at 24 months | 16.16 (7.4) | 14.75 (7.6) | 0.28 |
| **Rectal toxicity at 1 month** | | | |
| Grade 0 | 97.1% | 96.2% | 0.92 |
| Grade 1 | 1.9% | 3.8% |
| Grade 2 | 1% | | |
| **Rectal toxicity at 3 months** | | | |
| Grade 0 | 90.5% | 96.2% | 0.80 |
| Grade 1 | 9.5% | 3.8% |
| **Rectal toxicity at 6 months** | | | |
| Grade 0 | 95.3% | 83.9% | < 0.01 |
| Grade 1 | 4.7% | 16.1% |
| **Rectal toxicity at 12 months** | | | |
| Grade 0 | 86.7% | 93.3% | 0.76 |
| Grade 1 | 11.4% | 6.7% |
| Grade 2 | 1.9% | | |
| **Rectal toxicity at 18 months** | | | |
| Grade 0 | 91.4% | 89.5% | 0.65 |
| Grade 1 | 7.6% | 9.5% |
| Grade 2 | 1% | 1% |
| **Rectal toxicity at 24 months** | | | |
| Grade 0 | 89.5% | 92.3% | 0.48 |
| Grade 1 | 9.5% | 6.7% |
| Grade 2 | 1% | 1% |

IEEF-5 – five-item international index of erectile function, IPSS – international prostate symptom score, SD – standard deviation. Toxicity is scored using the CTCAE v.4 (common terminology criteria for adverse events).
pared to patients with LS, but his study included only 40 patients [22]. We found G1 toxicity to be slightly higher at 6 months in the IBCLS group, although post-operative parameters were similar in the two groups. G1 toxicity rates at 3, 12, and 24 months were comparable between the two groups, therefore, we can assume that the difference observed at 6 months may not be clinically significant.

It is known that patients treated with 125I low-dose-rate BT have overall very few complications [23]. During the first 4 years after BT, more than a half of patients maintain an IIEF-5 ≥ 16, with very rare severe erectile dysfunction [24]. In a series of 2,928 patients, erectile function was even preserved in more than 80% of young patients at 5 years [25]. Several parameters can influence potency after BT, and the dose to the penis bulb might be of importance [26]; after a 2-year follow-up, among patients who had no or weak erectile dysfunction (IIEF-5 ≥ 16) at baseline, 62% in the LS group and 59% in the IBCLS group presented no clinically relevant decrease in erectile function. The follow-up was however too short to assess the long-term effect on erectile function, as BT-related erectile disorders may occur after 2 years after implantation [25].

In our study, the reproducibility of the dosimetric plan was better in the LS group, illustrated by the ∆D90 (–13.6 ±16.4% and –29.3 ±8.0%, p < 0.001), which is explained by a lower D90 at 1 month in the IBCLS group. There was no clinical impact of this difference, but the follow-up was too short (especially in the IBCLS group) and the number of relapses too small to draw any conclusion. In a recent dosimetric study performed by Kaneda et al., there was a trend towards a lower post-operative D90, V150, and V100 with IBCLS compared to LS (118.8% vs. 127.2%; 51.7% vs. 66.7%; 0.44 ml vs. 0.61 ml, respectively, p < 0.01) [10]. Another retrospective study showed that procedures with LS were associated with intraoperative lower doses to the urethra and rectum compared to IBCLS [18]. In the opposite, Ishiyama et al. did not observe any post-operative dosimetric difference between IBCLS and LS in a prospective trial [27]. In our study, IBCLS allowed significantly lower dosimetric parameters to organs at risk; although, this difference did not appear on the post-operative planning.

IBCLS technique has advantages compared to LS. Activity required to treat a prostate of a given volume is lower with IBCLS than with LS [28]. Moreover, less post-implant seed migration have been observed when using the IBCLs technique [27,28,29], especially in the chest BT: HR = 7.9 (2.3-28.1) vs. HR = 15.9 (5.9-42.1), p < 0.0001, per 1,000 permanent prostate [11]. Using a coated vicryl to the surface of radioactive seeds may help to lower propensity of the seeds to slip from their initial implant location, thus maintaining dosimetric integrity and reducing lung and pelvic seed migration [30]. Moreover, coated seeds have a significant anchoring effect, which is particularly effective in reducing the number of apical seeds loss [2].

A multi-institutional retrospective analysis showed no dosimetric differences and no learning curve, but an extended operation time by up to 7 min for IBCLS [31]. We did not consider the first 40 patients treated with LS in order to exceed the learning curve, as a significant difference in the post-implant D90 exists for patients who received their implants after 40 procedures [6]. A very short learning curve of about five patients has been reported for IBCLS after an LS experience [31].

Our study has the advantage of having comparable homogeneous populations obtained through the matching procedure. However, it is mono-centric and retrospective in nature, with a limited number of patients and short follow-up. Indeed, it is known that IPSS significantly increases at 3 months following BT and returns to baseline by 36 months. However, in the recent study by Onishi et al., although total IPSS decreased between 12 and 36 months (10.1 to 8.81), the scores at 2 (9.89) and 3 years (8.81) were not significantly different from baseline (7.99) [32]. Similarly, Ohashi et al. found that the mean of post-implant IPSS peaked at 3 months, but decreased to a range that was within 2 points of the baseline score at one year in 70% of patients, in a cohort of 1,625 men treated with LDR-BT [21]. Thus, this allows an assumption that IBCLS would not be associated with higher urinary toxicity at a later time point. We also acknowledged that urinary toxicity was reported using the IPSS only, although patients can present with other symptoms, such as painful burning sensation during urination. The storage symptom, for instance, does not return to baseline at 36 months post-BT [32].

During this short follow-up, 3 patients presented a biochemical recurrence, with one in the LS group and two in the IBCLS group, all of them at 2 years post-implantation. This has already been studied by others. Herbert et al. did not find any difference in biochemical control between LS and IBCLS in 1,500 patients [33]. In another study by Hinnen et al. on 896 patients, those treated with LS presented less biochemical control, but androgen deprivation was allowed and could have biased results [34].

Conclusions

This study shows that prostatic BT with IBCLS is a safe technique, which may allow slightly lower doses to organs at risk and a potential lower impact on IPSS at 12 months compared to BT with LS; but overall, both techniques have similar toxicities profiles.

Disclosure

The authors report no conflict of interest.

References

1. D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
2. Bowes D, Gaztanaga M, Araujo C et al. A randomized trial comparing seed displacement of coated seeds to regular loose seeds at 30 days postimplant. Brachytherapy 2013; 12: 362-367.
3. Reed DR, Wallner KE, Merrick GS et al. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy 2007; 6: 129-134.
4. Nakano M, Yorozu A, Saito S et al. Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS): multi-institutional cohort study. *Radiother Oncol* 2015; 10: 228.

5. Zauls AJ, Ashenafi MS, Onicescu G et al. Comparison of intraoperatively built custom linked seeds versus loose seed gun applicator technique using real-time intraoperative planning for permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 2011; 81: 1010-1016.

6. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. *Acta Urol Esp* 2011; 35: 501-514.

7. Le Fur E, Malhaire JP, Nowak E et al. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation. *Brachytherapy* 2013; 12: 589-595.

8. Jarusevicius L, Inciura A, Juozaitiene E et al. Comparison of implant quality between loose and intra-operatively linked iodine-125 seeds in prostate cancer brachytherapy. *J Radiat Res* 2012; 53: 439-446.

9. Stone NN, Stock RG. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. *Tech Urol* 1995; 1: 72-80.

10. Kaneda T, Ohashi T, Sakayori M et al. Plan reproducibility of intraoperatively custom-built linked seeds compared to loose seeds for prostate brachytherapy. *J Contemp Brachytherapy* 2018; 10: 291-296.

11. Merrell KW, Davis BJ, Goulet CC et al. Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. *Brachytherapy* 2019; 18: 306-312.

12. Tanaka N, Fujimoto K, Hirao Y et al. Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. *Urology* 2009; 74: 407-411.

13. Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 1997; 49: 822-830.

14. Wiltshire KL, Brock KK, Haider MA et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. *Int J Radiat Oncol Biol Phys* 2007; 69: 1090-1099.

15. Nakai Y, Tanaka N, Asakawa I et al. Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer. *J Contemp Brachytherapy* 2019; 11: 331-338.

16. Zuber S, Weiss S, Baaske D et al. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review. *Radiother Oncol* 2015; 10: 49.

17. Rasmusson E, Gunnlaugsson A, Kjellen E et al. Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer. *Acta Oncol* 2016; 55: 1016-1021.

18. Major T, Agoston P, Frohlich G et al. Loose versus stranded seeds in permanent prostate brachytherapy: dosimetric comparison of intraoperative plans. *Phys Med* 2014; 30: 909-913.

19. Acosta O, Drean G, Osprina JD et al. Voxel-based population analysis for correlating local dose and rectal toxicity in prostate cancer radiotherapy. *Phys Med Biol* 2013; 58: 2591-2595.

20. Katayama N, Yorozu A, Maruo S et al. Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: Prospective cohort study in 2339 patients. *Brachytherapy* 2016; 15: 736-745.

21. Ohashi T, Yorozu A, Saito S et al. Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men: nationwide J-POPS multi-institutional prospective cohort study. *Int J Radiat Oncol Biol Phys* 2015; 93: 141-149.

22. Salibshkumar EP, Borg J, Yeung I, Cummins-Holder C et al. Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer. *Brachytherapy* 2008; 7: 200-205.

23. Guinot JL, Ricos JV, Tortajada MI et al. Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer. *J Contemp Brachytherapy* 2015; 7: 258-264.

24. Schoentgen N, Marolleau J, Delage F et al. Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. *J Contemp Brachytherapy* 2019; 11: 195-200.

25. Keyes M, Pickles T, Crook J et al. Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy. *Brachytherapy* 2015; 14: 334-341.

26. Chasseray M, Dissaux G, Bourbonne V et al. Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with (125)I low dose rate brachytherapy for localized prostate cancer. *Acta Oncol* 2019; 58: 1029-1035.

27. Ishiyama H, Satoh T, Kawakami S et al. A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 2014; 90: 134-139.

28. Kudchadker RJ, Swanson DA, Kuban DA et al. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded seed era? *Int J Radiat Oncol Biol Phys* 2008; 72: 623-627.

29. Katayama N, Takemoto M, Takamoto A et al. Comparison of implant quality between intraoperatively built custom-linked seeds and loose seeds in permanent prostate brachytherapy using sector analysis. *J Radiat Res* 2016; 57: 393-399.

30. Sarkar A, Donavari V, Zhang J et al. Prostate implant dosimetric outcomes and migration patterns between bio-absorbable coated and uncoted brachytherapy seeds. *Brachytherapy* 2013; 12: 356-361.

31. Ishiyama H, Satoh T, Yorozu A et al. Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy. *J Radiat Res* 2016; 57: 68-74.

32. Onishi K, Tanaka N, Miyake M et al. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. *Clin Transl Radiat Oncol* 2018; 14: 51-58.

33. Herbert C, Morris WJ, Hamm J et al. The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy. *Brachytherapy* 2011; 10: 442-448.

34. Hininen KA, Moerland MA, Battenmann JJ et al. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome. *Radiother Oncol* 2010; 96: 30-33.